Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
Peter Martin(Northwestern University), John P. Leonard(New York University), Paul J. Christos(Cornell University), Eric J. Feldman(The University of Texas MD Anderson Cancer Center), E Fusco(NewYork–Presbyterian Hospital), Jia Ruan(Cornell University), Amy Chadburn(Cornell University), Tsiporah B. Shore(Cornell University), Rubén Niesvizky(Cornell University), Rebecca Elstrom(Acentech (United States)), Patricia Glynn(NewYork–Presbyterian Hospital), Morton Coleman(Cornell University), Scott Ely(NewYork–Presbyterian Hospital), Michael W. Schuster(NewYork–Presbyterian Hospital), D M Knowles(Columbia University Irving Medical Center), Selina Chen‐Kiang(NewYork–Presbyterian Hospital), Malea Joyce(NewYork–Presbyterian Hospital), Richard R. Furman(Cornell University)
Cited by 76
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k